ABUS Annual Cash & Cash Equivalents
$26.29 M
-$4.49 M-14.59%
31 December 2023
Summary:
As of January 22, 2025, ABUS annual cash & cash equivalents is $26.29 million, with the most recent change of -$4.49 million (-14.59%) on December 31, 2023. During the last 3 years, it has fallen by -$25.97 million (-49.69%). ABUS annual cash & cash equivalents is now -84.24% below its all-time high of $166.78 million, reached on December 31, 2015.ABUS Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ABUS Quarterly Cash And Cash Equivalents
$31.85 M
-$30.94 M-49.28%
30 September 2024
Summary:
As of January 22, 2025, ABUS quarterly cash and cash equivalents is $31.85 million, with the most recent change of -$30.94 million (-49.28%) on September 30, 2024. Over the past year, it has dropped by -$11.26 million (-26.11%). ABUS quarterly cash and cash equivalents is now -86.29% below its all-time high of $232.28 million, reached on March 31, 2015.ABUS Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ABUS Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -14.6% | -26.1% |
| 3 y3 years | -49.7% | +3.5% |
| 5 y5 years | -28.9% | +3.5% |
ABUS Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -76.0% | at low | -70.9% | +81.7% |
| 5 y | 5-year | -76.0% | at low | -70.9% | +81.7% |
| alltime | all time | -84.2% | +3195.5% | -86.3% | +456.5% |
Arbutus Biopharma Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $31.85 M(-49.3%) |
| June 2024 | - | $62.79 M(+45.7%) |
| Mar 2024 | - | $43.10 M(+64.0%) |
| Dec 2023 | $26.29 M(-14.6%) | $26.29 M(+49.9%) |
| Sept 2023 | - | $17.53 M(-35.5%) |
| June 2023 | - | $27.20 M(-33.0%) |
| Mar 2023 | - | $40.57 M(+31.8%) |
| Dec 2022 | $30.78 M(-71.8%) | $30.78 M(+28.2%) |
| Sept 2022 | - | $24.00 M(-49.3%) |
| June 2022 | - | $47.32 M(-41.8%) |
| Mar 2022 | - | $81.33 M(-25.6%) |
| Dec 2021 | $109.28 M(+109.1%) | $109.28 M(+40.3%) |
| Sept 2021 | - | $77.88 M(+151.6%) |
| June 2021 | - | $30.95 M(-61.0%) |
| Mar 2021 | - | $79.42 M(+52.0%) |
| Dec 2020 | $52.25 M(+64.3%) | $52.25 M(-46.1%) |
| Sept 2020 | - | $96.92 M(+111.2%) |
| June 2020 | - | $45.90 M(+73.8%) |
| Mar 2020 | - | $26.42 M(-16.9%) |
| Dec 2019 | $31.80 M(-13.9%) | $31.80 M(-64.7%) |
| Sept 2019 | - | $90.08 M(+14.2%) |
| June 2019 | - | $78.87 M(-6.1%) |
| Mar 2019 | - | $83.97 M(+127.3%) |
| Dec 2018 | $36.94 M(-32.0%) | $36.94 M(+68.4%) |
| Sept 2018 | - | $21.93 M(+115.2%) |
| June 2018 | - | $10.19 M(-18.2%) |
| Mar 2018 | - | $12.46 M(-77.0%) |
| Dec 2017 | $54.29 M(+131.9%) | $54.29 M(+256.6%) |
| Sept 2017 | - | $15.22 M(-37.1%) |
| June 2017 | - | $24.21 M(-18.9%) |
| Mar 2017 | - | $29.85 M(+27.5%) |
| Dec 2016 | $23.41 M(-86.0%) | $23.41 M(-12.1%) |
| Sept 2016 | - | $26.63 M(-38.0%) |
| June 2016 | - | $42.97 M(-70.3%) |
| Mar 2016 | - | $144.77 M(-13.2%) |
| Dec 2015 | $166.78 M(+131.0%) | $166.78 M(-7.9%) |
| Sept 2015 | - | $181.09 M(-12.6%) |
| June 2015 | - | $207.21 M(-10.8%) |
| Mar 2015 | - | $232.28 M(+221.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2014 | $72.19 M(+5.0%) | $72.19 M(-7.7%) |
| Sept 2014 | - | $78.18 M(-8.3%) |
| June 2014 | - | $85.27 M(-36.5%) |
| Mar 2014 | - | $134.36 M(+95.5%) |
| Dec 2013 | $68.72 M(+46.1%) | $68.72 M(+92.0%) |
| Sept 2013 | - | $35.79 M(-7.6%) |
| June 2013 | - | $38.72 M(-10.1%) |
| Mar 2013 | - | $43.06 M(-8.4%) |
| Dec 2012 | $47.02 M(+422.8%) | $47.02 M(+721.7%) |
| Sept 2012 | - | $5.72 M(-16.1%) |
| June 2012 | - | $6.82 M(-22.2%) |
| Mar 2012 | - | $8.77 M(-2.6%) |
| Dec 2011 | $9.00 M(-27.1%) | $9.00 M(+1.3%) |
| Sept 2011 | - | $8.88 M(-11.4%) |
| June 2011 | - | $10.03 M(+5.6%) |
| Mar 2011 | - | $9.50 M(-23.1%) |
| Dec 2010 | $12.34 M(-47.0%) | $12.34 M(-19.9%) |
| Sept 2010 | - | $15.41 M(-10.7%) |
| June 2010 | - | $17.25 M(-5.1%) |
| Mar 2010 | - | $18.18 M(-22.0%) |
| Dec 2009 | $23.30 M(+8.2%) | $23.30 M(+83.4%) |
| Sept 2009 | - | $12.71 M(+6.1%) |
| June 2009 | - | $11.98 M(-49.7%) |
| Mar 2009 | - | $23.80 M(+10.5%) |
| Dec 2008 | $21.54 M(+2.0%) | $21.54 M(-20.0%) |
| Sept 2008 | - | $26.92 M(-7.3%) |
| June 2008 | - | $29.05 M(+49.7%) |
| Mar 2008 | - | $19.40 M(-8.2%) |
| Dec 2007 | $21.13 M(+334.3%) | $21.13 M(+0.1%) |
| Sept 2007 | - | $21.12 M(+0.2%) |
| June 2007 | - | $21.08 M |
| Dec 2006 | $4.87 M(-53.6%) | - |
| Dec 2005 | $10.48 M(-58.1%) | - |
| Dec 2004 | $24.99 M(-29.7%) | - |
| Dec 2003 | $35.56 M(+38.7%) | - |
| Dec 2001 | $25.63 M(+1151.5%) | - |
| Dec 2000 | $2.05 M(-81.2%) | - |
| Dec 1999 | $10.91 M(+1267.5%) | - |
| Dec 1998 | $797.60 K | - |
FAQ
- What is Arbutus Biopharma annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Arbutus Biopharma?
- What is Arbutus Biopharma annual cash & cash equivalents year-on-year change?
- What is Arbutus Biopharma quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Arbutus Biopharma?
- What is Arbutus Biopharma quarterly cash and cash equivalents year-on-year change?
What is Arbutus Biopharma annual cash & cash equivalents?
The current annual cash & cash equivalents of ABUS is $26.29 M
What is the all time high annual cash & cash equivalents for Arbutus Biopharma?
Arbutus Biopharma all-time high annual cash & cash equivalents is $166.78 M
What is Arbutus Biopharma annual cash & cash equivalents year-on-year change?
Over the past year, ABUS annual cash & cash equivalents has changed by -$4.49 M (-14.59%)
What is Arbutus Biopharma quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of ABUS is $31.85 M
What is the all time high quarterly cash and cash equivalents for Arbutus Biopharma?
Arbutus Biopharma all-time high quarterly cash and cash equivalents is $232.28 M
What is Arbutus Biopharma quarterly cash and cash equivalents year-on-year change?
Over the past year, ABUS quarterly cash and cash equivalents has changed by -$11.26 M (-26.11%)